May 3, 2019 - Hughes Hubbard's IP litigation team, led by partner Jim Dabney, helped secure a favorable decision for drugmaker Cipla related to its patent settlement with Amgen over sales of a generic version of calcium-control drug Sensipar.

A single sentence in a patent settlement prevents Amgen Inc. from halting sales of a generic version of its blockbuster calcium-control drug Sensipar, a Delaware federal judge ruled in an opinion released Friday. The opinion from U.S. District Judge Leonard P. Stark declined to halt an at-risk launch of generic cinacalcet by India-based drugmaker Cipla Ltd. According to Judge Stark, the upshot is "price erosion and loss of market share [that] are likely to be quite steep" for Sensipar, which earned $1.4 billion in the U.S. last year.

Click here to view full article.